[April 12, 2012]

Research and Markets: BioPharma Outsourcing Performance Report: Outsourcing Relationship from the CRO's Perspective and Benchmarks 53 Sponsor Companies

Dublin - Research and Markets (http://www.researchandmarkets.com/research/06422399/biopharma_outsourc) has announced the addition of the "BioPharma Outsourcing Performance" report to their offering.

This report, Biopharma Outsourcing Performance, examines the outsourcing relationship from the CRO's perspective and benchmarks 53 sponsor companies' outsourcing operations and practices, as well as provides metrics for short, average, and extended timelines for critical stages in the outsourcing decision process.

Companies Are Benchmarked on Factors Including:

- RFP quality

- RFP response times

- Responsiveness to questions

- Bid defense organization

- Protocol quality

Report Content:

This report contains the following three sections.

1. Positive Biopharma Performance

2. Turnaround Metrics

3. The Service Provider's View

- Delays in Patient Recruitment

- Selection Criteria Becoming More Important

- Service Provider Differentiation

An appendix of Charts and Graphs is also included within this report with responses to all questions asked in this study.

What Readers Will Learn:

Service Providers will benefit from understanding competitive strategies for differentiating themselves in the crowded and competitive CRO market.

- Which attributes your peers think are most important to your customers

- The turnaround time metrics around four parts of a RFP response (submission, bid defense, award notification, contract)

- How your peers trying to differentiate themselves

Biopharmaceutical Companies will receive the data they need to optimize their outsourcing processes, potentially saving millions by shortening timelines and beginning an important relationship with greater chances of success.

- Industry average turnaround metrics to gauge your performance

- Which sponsor companies (by size segment) are viewed as industry leading on seven performance metrics

- Business models CROs are using to differentiate themselves

- CRO views on patient recruitment delays

Companies Mentioned:

- Abbott

- Allergan

- Amgen

- AstraZeneca

- Biogen Idec

- Boehringer Ingelheim

- Cephalon

- Chugai

- Daiichi Sankyo

- Genzyme

- King Pharmaceuticals

- Kyowa Hakko Kirin

- Merck and Co

- Merck KGaA

- Mitsubishi (News - Alert) Tanabe

- Nycomed

- UCB

- Wyeth

- Celgene

- Eisai

- GlaxoSmithKline

- Johnson and Johnson

- Solvay

- Takeda

- Teva

- Shire

- Bayer

- Eli Lilly

- Novartis

- Bristol-Myers Squibb

- Roche

Genentech

- Pfizer

For more information visit http://www.researchandmarkets.com/research/06422399/biopharma_outsourc

[ Back To TMCnet.com's Homepage ]